Table 2 Ruxolitinib responses
From: Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Acute GVHD (n = 23) | ORR | CRR |
|---|---|---|
Overall response | 16/23 (69.5) | 5/23 (21.7) |
Response rate in grades 3–4 | 14/20 (70) | 5/20 (25) |
RR by organs | ||
Skin | 11/16 (68.8) | 3/16 (18.7) |
Gut | 14/21 (66.7) | 4/21 (19) |
Liver | 9/13 (69.2) | 3/13 (23) |
RR ≥ 3 lines of treatment | 9/12 (75) | |
And aGVHV grades 3–4 | 8/11 (72.7) | 2/11 (18.2) |
And skin involvement | 8/10 (80) | 2/9 (20) |
And gut involvement | 8/11 (72.7) | 1/11 (9) |
And liver involvement | 4/6 (66.7) | 1/6 (16) |
Chronic GVHD (n = 56) | ORR | CRR |
|---|---|---|
Overall response | 32/56 (57.1) | 2/56 (3.5) |
RR by grades | ||
Moderate | 17/28 (60.7) | 1/28 (3.5) |
Severe | 15/28 (53.5) | 1/28 (3.5) |
RR by organs | ||
Skin with sclerotic changes | 14/25 (56) | 0/25 (0) |
Lung | 16/26 (61.5) | 2/26 (7) |
Gut | 9/16 (56.3) | 2/16 (12) |
RR ≥3 lines of treatment | 17/32 (53.1) | 2/32 (6.3) |
And moderate plus severe | 17/32 (53.1) | 2/32 (6.3) |
cGVHD | ||
And skin involvement with sclerotic changes | 8/15 (53.3) | 0/15 (0) |
And lung involvement | 10/14 (71.4) | 2/14 (14.2) |
And gut involvement | 7/10 (70) | 2/10 (20) |
